Adlai Nortye Ltd. (ANL)
NASDAQ: ANL · Real-Time Price · USD
2.000
-0.040 (-1.96%)
Oct 31, 2024, 4:00 PM EDT - Market closed

Company Description

Adlai Nortye Ltd., a clinical-stage biotechnology company, focuses on the discovery and development of cancer therapies in the United States and Mainland China.

Its lead product is AN2025, a pan-phosphoinositide 3-kinase inhibitor, which is in Phase III clinical trial for the treatment of recurrent or metastatic head and neck squamous cell carcinomas.

The company is also developing AN0025, a small molecule prostaglandin E receptor 4 antagonist to modulate the tumor microenvironment that is in a Phase Ib clinical trial for the treatment of recurrent non-small cell lung cancer and urothelial cancer after anti-PD-1/PD-L1 treatments, recurrent triple-negative breast cancer, microsatellite stable colorectal cancer, and cervical cancer after standard of care treatments; and AN4005, an oral small-molecule PD-L1 inhibitor, which is in Phase I clinical trial to induce and stabilize PD-L1 dimerization and thereby disrupt the interaction between PD-1 and PD-L1.

Its preclinical candidates include AN8025, a multifunctional antibody as T cell and antigen-presenting cell modulator; AN1025, an oral small molecule degrader of ß-catenin; and AN9025, an oral small molecule pan-KRAS inhibitor.

The company was founded in 2004 and is based in Grand Cayman, the Cayman Islands.

Adlai Nortye Ltd.
Adlai Nortye logo
Country Cayman Islands
Founded 2004
IPO Date Sep 29, 2023
Industry Biotechnology
Sector Healthcare
Employees 127
CEO Yang Lu

Contact Details

Address:
Ugland House, PO Box 309
Grand Cayman, KY1-1104
Cayman Islands
Phone 848 230 7430
Website adlainortye.com

Stock Details

Ticker Symbol ANL
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
IPO Price $23.00
CIK Code 0001944552
ISIN Number US00704R1095
SIC Code 2834

Key Executives

Name Position
Yang Lu Chief Executive Officer and Chairman
Dr. Kaiyang Tang President
Wei Zhang Chief Financial Officer
Dr. Victoria Elizabeth Demby Ph.D. Senior Vice President and Global Head of Regulatory Affairs
Dr. Ngai Chiu Tse M.D., Ph.D. Head of Research and Development

Latest SEC Filings

Date Type Title
Aug 8, 2024 6-K Report of foreign issuer
Jul 3, 2024 6-K Report of foreign issuer
Jun 27, 2024 6-K Report of foreign issuer
May 24, 2024 6-K Report of foreign issuer
May 13, 2024 S-8 Securities to be offered to employees in employee benefit plans
Apr 19, 2024 20-F Annual and transition report of foreign private issuers
Apr 2, 2024 6-K Report of foreign issuer
Mar 4, 2024 SC 13G Statement of acquisition of beneficial ownership by individuals
Feb 15, 2024 SC 13G Statement of acquisition of beneficial ownership by individuals
Feb 15, 2024 SC 13G Statement of acquisition of beneficial ownership by individuals